IRTC Stock Price and Chart NASDAQ:IRTC

Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year. These returns cover a period from January 1, 1988 through July 31, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank.

iRhythm Technologies Announces Fourth Quarter and Full Year 2022 Financial Results

This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply. Compare
IRTC’s historical performance
against its industry peers and the overall market. Our Quantitative Research team models direct competitors or comparable companies
from a bottom-up perspective to find companies describing their business in a
similar fashion.

IRhythm Technologies, Inc. is a digital healthcare company, which engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. It also provides solutions that detect, predict, and prevent disease. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA. IRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company’s Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient’s heartbeats and ECG data.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. IRTC’s beta can be found in Trading Information at the top of this page.

iRhythm Technologies Inc.

The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy.

• The latest trend in earnings estimate revisions for the stock doesn’t suggest further strength…
• High-growth stocks tend to represent the technology, healthcare, and communications sectors.
• Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes.

It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California. 10 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for iRhythm Technologies in the last twelve months. The consensus among Wall Street research analysts is that investors should “moderate buy” IRTC shares. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system.

Latest IRTC News Press Releases

A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Provides a general description of the business conducted by this company. Upgrade to MarketBeat All Access to add more stocks to your watchlist. One share of IRTC stock can currently be purchased for approximately $94.20. Click the link below and we’ll send you MarketBeat’s guide to pot stock investing and which pot companies show the most promise.

Sign-up to receive the latest news and ratings for iRhythm Technologies and its competitors with MarketBeat’s FREE daily newsletter. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the working expenses bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. Plus, IRTC info will be updated daily in your Zacks.com Portfolio Tracker – also free. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.

Analyst Ratings

Clinical studies presented at Heart Rhythm 2023 build on the totality of clinical evidence that continue to highlight the value of iRhythm’s Zio products and services across a wide range of patient po… IRhythm Technologies’ stock is owned by a variety of retail and institutional investors. Insiders that own company stock include Daniel G Wilson, David A Vort, David A Vort, Douglas Devine, Kevin M King, Mark J Day, Merz Cathleen Noel Bairey, Patrick Michael Murphy and Quentin S Blackford. 20 employees have rated iRhythm Technologies Chief Executive Officer Kevin M. King on Glassdoor.com.

IRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn’t suggest further strength… According to 11 analysts, the average rating for IRTC stock is “Strong Buy.” The 12-month stock price forecast is $139.73, which is an increase of 48.33% from the latest price. Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. IRhythm Technologies issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd.

© 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.

Kevin M. King has an approval rating of 91% among the company’s employees. This puts Kevin M. King in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023. Zacks Earnings ESP https://1investing.in/ (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.

The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $485.00 million-$490.00 million, compared to the consensus revenue estimate of $483.78 million. NEW YORK–(BUSINESS WIRE)–Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, is investigating whether iRhythm Technologies, Inc. (“iRh… Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements.

Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks.

It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

• IRTC’s beta can be found in Trading Information at the top of this page.
• Additional studies presented at ACC.23/WCC reinforce the clinical value of the Zio suite of products and services Additional studies presented at ACC.23/WCC reinforce the clinical value of the Zio sui…
• Provides a general description of the business conducted by this company.
• Since then, IRTC shares have increased by 0.6% and is now trading at $94.20.
• The consensus among Wall Street research analysts is that investors should “moderate buy” IRTC shares.

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. We’d like to share more about how we work and what drives our day-to-day business.

(IRTC) raised $76 million in an initial public offering (IPO) on Thursday, October 20th 2016. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers. IRhythm Technologies’ stock was trading at $93.67 at the start of the year. Since then, IRTC shares have increased by 0.6% and is now trading at $94.20. Additional studies presented at ACC.23/WCC reinforce the clinical value of the Zio suite of products and services Additional studies presented at ACC.23/WCC reinforce the clinical value of the Zio sui…